Ovulation induction.
Methods to induce ovulation in anovulatory women have blossomed over the last three decades. The introduction of clomiphene citrate in 1960 allowed us for the first time to provoke follicle development in patients with normo or hyperestrogenic forms of anovulation. The development of human menopausal gonadotropins in the early 1960s gave us a much more powerful tool with which to influence ovulation in all forms of ovulatory disturbances. Elucidation of the pulsatile secretion of gonadotropin-releasing hormone together with its isolation and synthesis has allowed us to streamline our methods of inducing ovulation in hypothalamic amenorrheic patients by using endogenous control mechanisms to maximize both safety and effectiveness. However, there are problems yet to solve. Polycystic ovarian disease has long eluded our efforts to resolve its pathophysiology as well as to devise a consistently effective and safe means of treatment. Methods to restore ovulation in patients with polycystic ovarian disease refractory to clomiphene citrate is the quest of future investigations.
D000818:Animals; D002996:Clomiphene / Q000494:pharmacology; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000188:drug therapy*; D008297:Male; D008596:Menotropins / Q000494:pharmacology; D010062:Ovulation Induction / Q000379:methods*; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology; D011247:Pregnancy
D010906:Pituitary Hormone-Releasing Hormones; D002996:Clomiphene; D008596:Menotropins